Results 31 to 40 of about 20,082,992 (152)

RET proto-oncogene and thyroid cancer [PDF]

open access: yes, 1997
TheRET proto-oncogene has not only conclusively been identified as responsible for the three subtypes of the inherited cancer syndrome multiple endocrine neoplasia type 2 (MEN-2) but also shown to be involved in the molecular evolution of sporadic ...
Komminoth, Paul
core   +1 more source

Five‐Year Trends in Biomarker Testing and Targeted Therapy for NSCLC: A Patient‐Initiated Nationwide Survey in Japan

open access: yesCancer Science, EarlyView.
This nationwide survey reveals that comprehensive multigene testing for advanced NSCLC has rapidly expanded in Japan, steadily increasing the use of targeted therapies for rare oncogenic drivers. Despite these diagnostic advancements, approximately 30% of patients consistently remain untested, highlighting a persistent clinical gap in real‐world ...
Satoshi Ikeda   +9 more
wiley   +1 more source

NSAID ingestion augments training‐induced muscle hypertrophy and differentially affects muscle mRNA expression, but not strength gains, in trained men

open access: yesThe Journal of Physiology, EarlyView.
Abstract figure legend Schematic outlining the impact of NSAID ingestion on resistance exercise training‐induced changes in muscle morphology, function and gene networks relative to placebo ingestion in trained males. Abstract Non‐steroidal anti‐inflammatory drugs (NSAIDs) are widely overused in sports.
Joanne E. Mallinson   +6 more
wiley   +1 more source

Identification of Crucial Drug Targets and Pathways to Reprogram Drug Resistance Through Epigenetic Modulation in Advanced Lung Cancer Using Integrated Bioinformatics Approach

open access: yesComputational and Systems Oncology, Volume 6, Issue 1, December 2026.
ABSTRACT Resistance to chemotherapy, which is demonstrated in almost every patient with advanced‐stage lung cancer (ALC), underscores an urgent need to unravel the underlying molecular mechanisms and identify novel strategies to overcome drug resistance. In the present study, an attempt was made to identify epigenetic targets and modulators that can be
Okibur Rahman   +2 more
wiley   +1 more source

Clinical Implementation and Oncological Relevance of Molecular Profiling in Brain Metastases Patients—A Multicenter Retrospective Cohort Study

open access: yesInternational Journal of Cancer, Volume 159, Issue 10, Page 2562-2574, 15 November 2026.
While current guidelines recommend the analysis of established cancer driver genes in brain metastases, little is known about its real‐life implementation. This multicenter study revealed an upward trend in the profiling rates of surgically treated brain metastases over the past decade, with up to 60% of brain metastases samples undergoing analysis ...
Maria Nikolaeva   +25 more
wiley   +1 more source

Utility of Fine Needle Aspiration Supernatant for Real‐Time PCR–Based Mutation Analysis in Non–Small Cell Lung Cancer

open access: yesDiagnostic Cytopathology, Volume 54, Issue 11, Page 805-811, November 2026.
ABSTRACT Background The emergence of personalized therapy and molecular sequencing has significantly transformed the management of advanced non–small cell lung carcinoma (NSCLC). Supernatants obtained from fine needle aspiration (FNA) have been shown to be a reliable source of high‐quality nucleic acid for molecular testing.
Adeyinka Akinsanya   +9 more
wiley   +1 more source

Cancer Risk in Marfan Syndrome: A Swedish Population‐Based Cohort Study

open access: yesInternational Journal of Cancer, Volume 159, Issue 7, Page 1707-1714, 1 October 2026.
The cancer risk in Marfan syndrome, an autosomal dominant connective tissue disorder, largely remains to be explored. In this population‐based matched cohort study of 1544 Swedish patients, the overall cancer risk in adults with Marfan syndrome showed no significant increase, except for the risk of endocrine tumours with a nearly threefold increase ...
Ida Nordgren   +8 more
wiley   +1 more source

Envonalkib Versus Crizotinib in Treatment‐Naive ALK‐Positive Non‐Small Cell Lung Cancer: Final Efficacy and Biomarker Analyses of the Randomized Phase III Study

open access: yesMedComm, Volume 7, Issue 10, October 2026.
Envonalkib provides robust and durable benefit in treatment‐naïve ALK‐positive NSCLC, with median PFS of 30.4 months versus 12.0 months for crizotinib. Exploratory biomarker analyses showed that concurrent driver alterations and p53 pathway dysfunction reduce treatment efficacy.
Jie Huang   +25 more
wiley   +1 more source

Cancer Cell Metastasis: From Molecular Mechanisms to Therapeutic Strategies

open access: yesMedComm, Volume 7, Issue 10, October 2026.
The schematic representation of intrinsic and extrinsic influences of cancer cell metastasis. Genomic evolution of metastatic tumor cells (MTCs) promotes their metastatic phenotypes and reconstruct the primary tumor microenvironment. During MTCs migration along different routes (blood circulation, lymphatic vessels, and perineuronal spaces), the ...
Yupeng Zhao   +7 more
wiley   +1 more source

Detection of RET oncogene activation in human papillary thyroid carcinomas by in situ hybridisation.

open access: yes, 1992
We have recently reported the activation of a new oncogene in human papillary thyroid carcinomas. This oncogene, named PTC, is a novel rearranged version of the ret proto-oncogene. In fact PTC is the product of the fusion of the tyrosine kinase domain of
M. Grieco   +17 more
core   +2 more sources

Home - About - Disclaimer - Privacy